Vol 16, No 2 (2020)
Research paper
Published online: 2019-11-19

open access

Page views 1168
Article views/downloads 771
Get Citation

Connect on Social Media

Connect on Social Media

Retrospective assessment of Lung-RADS® performance in the Silesian Lung Cancer Screening Pilot Study

Ewa Wachuła1, Sylwia Szabłowska-Siwik1, Damian Czyżewski2, Jerzy Kozielski3, Wojciech Rogowski4, Mariusz Adamek2
Oncol Clin Pract 2020;16(2):52-55.

Abstract

Background. A high percentage of false positive results, observed in lung cancer screening studies with low-dose computed tomography (LDCT), caused the modification of radiological assessment methods. According to the International Early Lung Cancer Action Program (IELCAP) all non-calcified nodules with a dimension ≥ 4 mm were considered as positive. Implementation of classification the Lung CT screening Reporting and Data System (Lung-RADS®) recommends additional testing only for nodules ≥ 6 mm, which reduced of false positive results.

Methods. We provided a retrospective analysis of 601 LDCT scans, in asymptomatic volunteers of Pilot Silesian Study of Early Lung Cancer Detection, with at least 20 pack-years of cigarette smoking. The analysis of non- and invasive interventions was done. Assessment of nodules according to the Lung-RADS® system was done. Then the percentage of interventions that could be avoided using the Lung-RADS® criteria was estimated.

Results. In total, 1016 nodules were identified in 265 participants. The positive result of screening was defined as a presence of solid or part-solid nodule ≥ 5 mm and ≥ 8 mm in the case of a nonsolid nodule in line with the IELCAP protocol. Screening based on the IELCAP protocol resulted in 200 positive results and based on Lung-RADS® in the 116 positives. The frequency of lung cancers among participants with a positive result was 7 of 200 (4.0%) (95% CI: 1.0%, 6.0%) for IELCAP and 7 of 116 (6.0%) (95% CI: 2.7%, 9.3%) for Lung-RADS®. The Lung-RADS® criteria reduced number of non- and invasive procedures by 48.8% and 24.1%, compared to IELCAP protocol.

Conclusions. Adopting the Lung-RADS® classification system may reduce harms and improve the efficiency of lung cancer screening programs.

Article available in PDF format

View PDF Download PDF file

References

  1. Aberle DR, Adams AM, Berg CD, et al. National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5): 395–409.
  2. International Early Lung Cancer Action Program protocol. http://www.ielcap.org/sites/default/files/ielcap.pdf.
  3. Lung CT Screening Reporting & Data System. https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Lung-Rads.
  4. Henschke CI, Yip R, Yankelevitz DF, et al. International Early Lung Cancer Action Program Investigators*. Definition of a positive test result in computed tomography screening for lung cancer: a cohort study. Ann Intern Med. 2013; 158(4): 246–252.
  5. Clark TJ, Flood TF, Maximin ST, et al. Lung CT Screening Reporting and Data System Speed and Accuracy Are Increased With the Use of a Semiautomated Computer Application. J Am Coll Radiol. 2015; 12(12 Pt A): 1301–1306.
  6. Central Statistical Office. Health status of population in Poland in 2014. , Warsaw 2016: 98–99.
  7. Public Opinion Research Center (CBOS) report in Polish “Smoking Cigarettes”. 2019; 104: 1–20.
  8. Szablowska-Siwik S, Wachula E, Czyzewski D, et al. PUB073 Lung Cancer Screening with LDCT – Results of a Small Cohort Continual Monitoring (Pilot Silesian Study). J Thorac Oncol. 2017; 12(11): S2389–S2390.
  9. Pinsky PF, Gierada DS, Black W, et al. Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment. Ann Intern Med. 2015; 162(7): 485–491.
  10. Rzyman W, Szurowska E, Adamek M. Implementation of lung cancer screening at the national level: Polish example. Transl Lung Cancer Res. 2019; 8(Suppl 1): S95–S9S105.
  11. Horeweg N, van Rosmalen J, Heuvelmans MA, et al. Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening. Lancet Oncol. 2014; 15(12): 1332–1341.